Key result
Hepatic steatosis correlated with visceral fat and inflammatory biomarkers, but had no significant association with coronary, aortic, or carotid calcium.
Why the study?
Is hepatic steatosis associated with subclinical atherosclerosis and inflammatory biomarkers in a cohort enriched for type 2 diabetes?
Cross-Sectional (n=623)
Is hepatic steatosis associated with subclinical atherosclerosis and inflammatory biomarkers in a cohort enriched for type 2 diabetes?
Hepatic steatosis is associated with pro-atherogenic biomarkers and visceral fat but not directly with subclinical atherosclerosis, suggesting it is an epiphenomenon of a systemic pro-atherogenic state rather than a direct mediator of cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Hepatic steatosis should not yet inform subclinical atherosclerosis risk stratification in T2D; leaves open its role as epiphenomenon of visceral inflammation.
OBJECTIVES: To explore mechanisms whereby hepatic steatosis may be associated with cardiovascular risk, we investigated cross-sectional relationships between hepatic steatosis, regional fat accumulation, inflammatory biomarkers, and subclinical measures of atherosclerosis in the Diabetes Heart Study. METHODS: The Diabetes Heart Study is a family study of sibling pairs concordant for type 2 diabetes. A subset of 623 randomly selected participants was evaluated for hepatic steatosis, defined as a liver:spleen attenuation ratio of <1.0 by computed tomography. We quantified visceral fat, subcutaneous fat, coronary, aortic, and carotid artery calcium by computed tomography; and carotid atherosclerosis by ultrasound. Associations between the liver:spleen attenuation ratio and these factors were expressed as Spearman correlations. RESULTS: After adjustment for age, race, gender, body mass index, and diabetes status, the liver:spleen attenuation ratio correlated with visceral fat (r =-0.22, P < 0.0001) and subcutaneous fat (r =-0.13, P= 0.031). Hepatic steatosis was associated with lower high-density lipoprotein (r = 0.21, P < 0.0001), higher triglycerides (r =-0.25, P < 0.0001), higher C-reactive protein (r =-0.095, P= 0.004), and lower serum adiponectin (r = 0.34, P < 0.0001). There were no significant associations between the liver:spleen attenuation ratio and coronary, aortic, or carotid calcium, or carotid intimal thickness. CONCLUSIONS: This suggests that hepatic steatosis is less likely a direct mediator of cardiovascular disease and may best be described as an epiphenomenon. The strong correlations between pro-atherogenic biomarkers, visceral fat, and elements of the metabolic syndrome suggest that hepatic steatosis reflects more than general adiposity, but represents a systemic, inflammatory, pro-atherogenic adipose state.
No takes yet. Share an insight, caveat, or question.
McKimmie et al. (2008) conducted a cross-sectional in Type 2 diabetes (n=623). Hepatic steatosis was evaluated on Associations between liver:spleen attenuation ratio and regional fat accumulation, inflammatory biomarkers, and subclinical measures of atherosclerosis. Hepatic steatosis correlated with visceral fat and inflammatory biomarkers, but had no significant association with coronary, aortic, or carotid calcium.
Synapse has enriched 10 related papers. Consider them for comparative context: